{"id":"e3810","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Insomnia"}]},"_chembl":{"chemblId":"CHEMBL2180605","moleculeType":"Small molecule","molecularWeight":"479.96"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PDE10A is predominantly expressed in medium spiny neurons of the striatum and is involved in dopamine and glutamate signaling. By inhibiting PDE10A, E3810 enhances cAMP and cGMP signaling, which modulates neuronal activity and may restore balance in dysregulated neural circuits. This mechanism is hypothesized to be beneficial in neuropsychiatric and neurodegenerative conditions.","oneSentence":"E3810 is a small-molecule inhibitor of phosphodiesterase 10A (PDE10A) that increases intracellular cyclic nucleotide signaling in the brain.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:10:26.420Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Parkinson's disease psychosis"}]},"trialDetails":[{"nctId":"NCT02053636","phase":"PHASE2","title":"A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2013-12","conditions":"Breast Cancer","enrollment":76},{"nctId":"NCT01283945","phase":"PHASE1, PHASE2","title":"Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2010-07","conditions":"Solid Tumors","enrollment":134},{"nctId":"NCT03992131","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)","status":"TERMINATED","sponsor":"pharmaand GmbH","startDate":"2019-06-28","conditions":"Ovarian Cancer, Triple-negative Breast Cancer, Urothelial Carcinoma","enrollment":25},{"nctId":"NCT04151563","phase":"PHASE1, PHASE2","title":"A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2021-04-15","conditions":"Carcinoma, Non-small Cell Lung Cancer","enrollment":""},{"nctId":"NCT02135107","phase":"PHASE3","title":"A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2013-09","conditions":"Gastroesophageal Reflux Disease","enrollment":517},{"nctId":"NCT04042116","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor","status":"SUSPENDED","sponsor":"Clovis Oncology, Inc.","startDate":"2019-07-29","conditions":"Advanced Solid Tumor, Gynecologic Cancer","enrollment":227},{"nctId":"NCT02202746","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Clovis Oncology, Inc.","startDate":"2014-09-09","conditions":"Breast Cancer, Metastatic Breast Cancer, MBC","enrollment":178},{"nctId":"NCT04254471","phase":"PHASE2, PHASE3","title":"This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients","status":"UNKNOWN","sponsor":"Haihe Biopharma Co., Ltd.","startDate":"2019-11-14","conditions":"Extensive-stage Small Cell Lung Cancer","enrollment":313},{"nctId":"NCT02109016","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations","status":"TERMINATED","sponsor":"Clovis Oncology, Inc.","startDate":"2014-04","conditions":"Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer, NSCLC","enrollment":18},{"nctId":"NCT02747797","phase":"PHASE2","title":"Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations","status":"WITHDRAWN","sponsor":"Teresa Helsten, MD","startDate":"2017-04","conditions":"Advanced Cancer","enrollment":""},{"nctId":"NCT03260179","phase":"PHASE1","title":"Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810","status":"UNKNOWN","sponsor":"Haihe Biopharma Co., Ltd.","startDate":"2017-08-31","conditions":"Advanced Solid Tumor, Advanced/Metastatic Colorectal Cancer","enrollment":60},{"nctId":"NCT03117101","phase":"PHASE1","title":"Study of the AL3810 in the Treatment of Advanced Solid Tumor","status":"COMPLETED","sponsor":"Haihe Biopharma Co., Ltd.","startDate":"2014-03","conditions":"Advanced Solid Tumors","enrollment":17},{"nctId":"NCT01398410","phase":"PHASE2, PHASE3","title":"Long-term Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2011-12","conditions":"Gastric Ulcers Duodenal Ulcers Caused by Low-dose Aspirin","enrollment":405},{"nctId":"NCT01397448","phase":"PHASE2, PHASE3","title":"Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2011-07","conditions":"Gastric or Duodenal Ulcers Caused by Low-dose Aspirin","enrollment":472},{"nctId":"NCT01089543","phase":"PHASE2","title":"A Study of E3810 for Japanese Subjects With Functional Dyspepsia (SAMURAI Study: Suppression of Acid Milieu With Rabeprazole Improving Functional Dyspepsia ) (Study E3810-J081-204)","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2010-04","conditions":"Functional Dyspepsia","enrollment":338},{"nctId":"NCT01153659","phase":"PHASE1","title":"A Study to Evaluate the Effect on 24-hour, Intragastric pH of RAB ER 50-mg Capsules Compared With Esomeprazole (Nexium) 40 mg Capsules and Rabeprazole (Aciphex) 20-mg Tablets","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2010-07","conditions":"Healthy","enrollment":90},{"nctId":"NCT01085708","phase":"PHASE1","title":"A Pilot Cross-over Bioequivalence Study of E3810 for Healthy Japanese Male (Under Postprandial Condition)","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2010-04","conditions":"Healthy","enrollment":16},{"nctId":"NCT01085695","phase":"PHASE1","title":"Study of E3810 for Healthy Japanese Male (Under Fasting Condition)","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2010-04","conditions":"Healthy","enrollment":16},{"nctId":"NCT01202071","phase":"PHASE2","title":"A Clinical Pharmacological Study of Rabeprazole Sodium in Japanese Healthy Adult Male Volunteers (Study E3810)","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2010-09","conditions":"Healthy","enrollment":24},{"nctId":"NCT00770913","phase":"PHASE2, PHASE3","title":"Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2008-10","conditions":"Refractory Reflux Esophagitis","enrollment":337},{"nctId":"NCT00165672","phase":"PHASE3","title":"A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2005-05","conditions":"Non-erosive Gastroesophageal Reflux Disease","enrollment":26},{"nctId":"NCT00165646","phase":"PHASE3","title":"A Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux Disease","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2004-09","conditions":"Non-erosive Gastroesophageal Reflux Disease","enrollment":288},{"nctId":"NCT00236184","phase":"PHASE3","title":"E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2005-10","conditions":"Heartburn","enrollment":629},{"nctId":"NCT00236197","phase":"PHASE3","title":"E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2005-10","conditions":"Heartburn","enrollment":619}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":40,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Aciphex"],"phase":"phase_3","status":"active","brandName":"E3810","genericName":"E3810","companyName":"Eisai Co., Ltd.","companyId":"eisai-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"E3810 is a small-molecule inhibitor of phosphodiesterase 10A (PDE10A) that increases intracellular cyclic nucleotide signaling in the brain. Used for Schizophrenia, Parkinson's disease psychosis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}